For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Danaher Corporation (DHR) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -23 (−100…+100 Quality+Value blend) · Quality 42 · Value -77 · Sentiment -10 (timing only, not weighted) · Composite fair value $121.16 vs $199.66 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Danaher Corporation
DHR NYSEDanaher Corporation is a leading science and technology company that designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. It operates primarily through three key segments: Biotechnology, which provides tools and services for bioprocessing, genomics, and proteomics; Life Sciences, offering advanced instrumentation for research in microscopy, flow cytometry, and mass spectrometry; and Diagnostics, delivering clinical instruments, software, and consumables for laboratory diagnostics, pathology, and healthcare settings. Danaher Corporation's portfolio includes diagnostic equipment, digital imaging systems, optical instruments, microscopes, water quality control systems, and disinfection solutions, serving healthcare providers, research institutions, pharmaceutical companies, and industrial clients. These offerings support critical applications in drug discovery, disease diagnosis, environmental monitoring, and quality assurance across global markets. Founded in 1984 and headquartered in Washington, District of Columbia, Danaher Corporation plays a vital role in advancing scientific innovation and improving health outcomes through its integrated solutions.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 5.05
Total Equity: $52.54B
Shares: 716,100,000
Total Debt: $18.42B
Cash: $4.62B
EBITDA: $7.14B
Total Debt: $18.42B
Cash: $4.62B
Revenue: $24.57B
Revenue: $24.57B
Revenue: $24.57B
Total Equity: $52.54B
Tax Rate: 15.0%
Equity: $52.54B
Total Debt: $18.42B
Cash: $4.62B
Current Liabilities: $6.81B
Long-Term Debt: $18.42B
Total Debt: $18.42B
Total Equity: $52.54B
Shares: 716,100,000
Shares: 716,100,000
CapEx: -$1.16B
Shares: 716,100,000
Stock Price: $194.65
Net Income: $3.61B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 5, 2026 9:35am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $29.5B | $31.5B | $23.9B | $23.9B | $24.6B |
| Cost of Revenue | $11.5B | $12.5B | $9.9B | $9.7B | $10.0B |
| Gross Profit | $18.0B | $18.9B | $14.0B | $14.2B | $14.5B |
| Operating Expenses | $10.5B | $10.3B | $8.8B | $9.3B | $9.8B |
| Operating Income | $7.5B | $8.7B | $5.2B | $4.9B | $4.7B |
| Net Income | $6.4B | $7.2B | $4.8B | $3.9B | $3.6B |
| EBITDA | $9.6B | $10.9B | $7.4B | $7.2B | $7.1B |
| EPS | $8.77 | $9.80 | $6.44 | $5.33 | $5.07 |
| EPS (Diluted) | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 |
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:35am (18d ago)| Metric | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | $6.0B | $5.9B | $2.1B | $4.6B |
| Total Current Assets | — | $15.9B | $13.9B | $9.5B | $12.8B |
| Total Assets | — | $84.4B | $84.5B | $77.5B | $83.5B |
| Current Liabilities | — | $8.4B | $8.3B | $6.8B | $6.8B |
| Long-Term Debt | — | $19.1B | $16.7B | $15.5B | $18.4B |
| Total Liabilities | — | $34.3B | $31.0B | $28.0B | $30.9B |
| Total Equity | — | $50.1B | $53.5B | $49.6B | $52.5B |
| Retained Earnings | — | $39.2B | $41.1B | $44.2B | $46.9B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 11:39am (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $8.4B | $8.5B | $7.2B | $6.7B | $6.4B |
| Capital Expenditure | -$1.3B | -$1.2B | -$1.4B | -$1.4B | -$1.2B |
| Free Cash Flow | $7.1B | $7.4B | $5.8B | $5.3B | $5.3B |
| Acquisitions (net) | -$11.0B | -$637.0M | -$5.6B | -$558.0M | $0 |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | -$742.0M | -$818.0M | -$821.0M | -$768.0M | -$878.0M |
| Stock Buybacks | — | $0 | $0 | -$6.0B | -$3.1B |
| Net Change in Cash | -$3.4B | $3.4B | -$131.0M | -$3.8B | $2.5B |
Growth Trends (YoY %)
Last updated: Aug 5, 2026 9:35am (18d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +6.9% | -24.1% | -0.1% | +2.9% |
| Gross Profit Growth | +5.6% | -25.9% | +1.2% | +2.2% |
| Operating Income Growth | +16.4% | -40.1% | -6.5% | -3.6% |
| Net Income Growth | +12.1% | -33.9% | -18.2% | -7.3% |
| EBITDA Growth | +13.3% | -32.5% | -2.1% | -1.1% |
Dividend History (Last 20)
Last updated: Aug 5, 2026 9:35am (18d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-26 | $0.40 | — | — | — |
| 2026-03-27 | $0.40 | — | — | — |
| 2025-12-26 | $0.32 | — | — | — |
| 2025-09-26 | $0.32 | — | — | — |
| 2025-06-27 | $0.32 | — | — | — |
| 2025-03-28 | $0.32 | — | — | — |
| 2024-12-27 | $0.27 | — | — | — |
| 2024-09-27 | $0.27 | — | — | — |
| 2024-06-28 | $0.27 | — | — | — |
| 2024-03-27 | $0.27 | — | — | — |
| 2023-12-28 | $0.24 | — | — | — |
| 2023-10-11 | $0.27 | — | — | — |
| 2023-06-29 | $0.24 | — | — | — |
| 2023-03-30 | $0.24 | — | — | — |
| 2022-12-29 | $0.22 | — | — | — |
| 2022-09-29 | $0.22 | — | — | — |
| 2022-06-23 | $0.22 | — | — | — |
| 2022-03-24 | $0.22 | — | — | — |
| 2021-12-29 | $0.19 | — | — | — |
| 2021-09-29 | $0.19 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:48Even the bull case prices 59% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 67%.
| Case | Growth | Margin | Fair value | vs price ($199.66) |
|---|---|---|---|---|
| Bull — recovery | +5% | 19.4% | $81.99 | -59% |
| Base — stabilizes | +3% | 16.9% | $68.42 | -66% |
| Bear — keeps slipping | +2% | 14.4% | $56.08 | -72% |
| Stress — last quarter repeats | +4% | 16.2% | $66.69 | -67% |
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers tell a story of stalled compounding dressed up in a premium multiple. Revenue has essentially flatlined: $31.5B in 2022 → $23.9B in 2023 → $23.9B in 2024 → $24.6B in 2025, and net income has collapsed from $7.21B (2022) to $3.61B (2025) — a ~50% earnings decline over three years while the stock trades at 39x trailing P/E and 6.3x EV/revenue. ROE is 6.9% and ROIC is 6.0%, both below any reasonable WACC for a levered ($18.4B debt) healthcare conglomerate. The most recent quarter (Q2 2026) shows revenue of $6.27B with 13.9% net margin — decent sequential revenue but the margin has slid from the 17%+ prints of late 2025/early 2026. Recent revenue YoY is only 2.9% and earnings YoY is -7.3%. This is not a growth story; it's a mature industrial trading like a platform SaaS.
I broadly agree with the synthesis verdict of overvalued, but I think the synthesis fair value of ~$105-113 is arguably too harsh and the narrative model's read is closer to right on *why* the premium exists but wrong on how quickly it deflates. FCF of $5.26B on a $137B market cap is a 3.8% FCF yield — for a business growing FCF at negative 4.6% CAGR, that's rich but not absurd if you believe bioprocessing destocking is genuinely transient. The bulls have one legitimate anchor: Q4 2025 ($6.84B rev, 17.5% margin) and Q1 2026 ($5.95B, 17.3%) showed the margin structure is intact when volumes cooperate. If organic growth reaccelerates to 5-6% and margins normalize to 18-19% operating, you get to $5.5-6B in normalized net income, which at a defensible 22-25x justifies $130-160. That's still 20-33% below current, but it's not the $105 the DCF suggests.
The contrarian case worth taking seriously: bioprocessing is a real secular growth market (GLP-1, cell/gene therapy, biologics broadly), and Danaher's Cytiva/Pall franchise is genuinely hard to displace once designed into a customer's process — regulatory switching costs are enormous. If the destocking cycle bottoms in H2 2026 (Q2 rev of $6.27B is up from the $5.74-5.94B trough range), you could see 2027 estimates get marked up meaningfully. The insider activity is uninformative — option exercises and RSU vesting, no meaningful open-market buying or selling either way, which contradicts the "neutral" framing only in that it's really "no signal." I'd flag the pre-flight's citing of "27x pre-COVID P/E" as suspect — DHR traded 20-25x pre-2020, so 39x is genuinely stretched even by its own history, not just versus peers.
Where the models converge and I agree: this is a high-quality business at a demanding price with decelerating fundamentals. Where I push back on the synthesis: the -47% downside to $105 assumes DCF captures the option value of the M&A engine and the terminal moat, and it doesn't — Danaher has historically compounded book value at 12-15% through disciplined capital allocation, which no DCF prices correctly. My fair value range is $140-165, meaning DHR is 15-25% overvalued, not 47%. That's still a pass at $194, but it's not a short. The catalyst to watch is Q3 2026 organic growth — if bioprocessing shows sequential acceleration and Cytiva book-to-bill exceeds 1.0, the premium is defensible; if it doesn't, multiple compression toward 28-30x is the base case and you're looking at $150. I'd wait for either a re-rating to the low $160s or evidence of organic reacceleration before committing capital. The synthesis is directionally right; the magnitude is overstated.
GPT Reading
Danaher still looks like a very good business trading at a price that assumes it is a great growth business again, and the data here does not show that turn yet. Revenue has stabilized, yes: 2025 annual sales were $24.57B versus $23.88B in 2024, and the last four quarters sum to roughly $25.1B, so the top line is inching forward. But the earnings power underneath has not recovered with the same consistency. Net income fell from $7.21B in 2022 to $4.76B in 2023, $3.90B in 2024, and $3.61B in 2025. Operating income has followed the same pattern, from $8.69B in 2022 to $4.69B in 2025, cutting operating margin from 27.6% to 19.1%. A 39.3x P/E and 21.5x EV/EBITDA multiple might be defendable for a business with high-teens earnings growth or clear margin expansion ahead; they are hard to defend for one with 1.4% revenue CAGR over the recent measured period and negative earnings CAGR.
The quarterlies reinforce that this is not just a stale annual comparison. Revenue in the most recent quarter was $6.27B, up from $5.94B a year earlier, which is healthy enough on the surface, but net income was $870M versus $555M in that easy comparison quarter and still well below the $1.20B produced in 2025-12 or the $1.03B in 2026-03. Margins are bouncing between 9.3% and 17.5%, which is not what you pay a premium multiple for unless you have very high confidence the trough is over. Instead, what I see is a company generating respectable but not premium-quality incremental economics right now: 2025 gross margin was still strong at 59.1%, yet ROIC was only 6.0% and ROE 6.9%, both underwhelming relative to the valuation and relative to the “compounder” reputation embedded in the stock.
Cash flow is the main thing keeping me from becoming outright aggressive on the short side. Danaher produced $6.42B of operating cash flow and $5.26B of free cash flow in 2025, which is real money, and the balance sheet is perfectly manageable with $18.42B debt against $4.62B cash and $52.54B equity. On a free-cash-flow basis, though, investors are still paying about a 3.8% yield on the current market cap, before giving credit for debt. That is not cheap for a company whose FCF has also drifted down from the pandemic period and whose latest earnings trend remains negative. The issue is less balance-sheet risk than valuation discipline: this is a high-quality franchise, but the market is still capitalizing it like the Danaher Business System can reliably pull mid-to-high single-digit organic growth plus margin accretion out of a much larger, slower base. The reported numbers do not prove that.
The best counterargument is straightforward and serious: Danaher may be in the late innings of a cyclical digestion rather than a structural slowdown. Revenue has resumed growth, the last four quarters are ahead of the prior four, free cash conversion remains strong, gross margins remain elite near 59%, and the company has historically earned a premium because it reallocates capital better than most diversified healthcare peers. If the 2025-06 quarter’s 9.3% net margin was the true trough, then the rebound to 15.0%, 17.5%, 17.3%, and 13.9% afterward could be the early shape of normalization. In that scenario, the stock is not 39x “normal” earnings but something closer to a temporary high-teens multiple on trough-depressed earnings power. That case also leans on the fact that insiders are not showing meaningful bearish signals here; transactions look administrative rather than distributive.
What would change my mind is not another quarter of modest revenue growth; it is evidence that Danaher can convert that growth back into durable earnings and returns. If annualized revenue can push above $26B while operating margin climbs back above 22% and net income heads back toward $4.5B-$5.0B, the current multiple starts looking more defensible. I would also need to see ROIC move materially above 6% and free cash flow sustain well above $6B without leverage rising. Absent that, I think the stock remains priced for a recovery that is only partially visible in the data.
Grok Reading
The numbers tell a story of a post-pandemic hangover that has not resolved into the re-acceleration the multiple demands. Danaher printed $24.57B in 2025 revenue, a meager 2.9% lift off the $23.88B trough of 2024 and still 22% below the $31.47B COVID peak of 2022. Net income has marched steadily lower—$7.21B to $4.76B to $3.90B to $3.61B—while trailing twelve-month earnings power sits near $3.8B against a $137B enterprise. That produces a 39x P/E, 21.5x EV/EBITDA and 6.3x EV/sales for a business whose revenue CAGR over the measurable window is 1.4%, earnings CAGR is –12.9%, and FCF CAGR is –4.6%. Quarterly progression is choppy rather than decisive: the June 2026 quarter delivered $6.27B revenue and a 13.9% net margin, down from the 17%+ prints earlier in the year, confirming that operating leverage is not compounding cleanly. Returns on capital have collapsed to levels that no longer justify any premium—ROE 6.9%, ROIC 6.0%, ROA 4.3%—while the balance sheet remains merely adequate (net debt roughly $13.8B, debt/equity 0.35) rather than a fortress that could underwrite aggressive multiple expansion. Free cash flow of $5.26B is high quality and covers the modest dividend with room, but cash generation alone cannot paper over a valuation that prices in mid-teens growth the income statement has not delivered for three consecutive years.
The market is clearly paying for the Danaher Business System narrative and the hope that bioprocessing destocking is purely cyclical. Yet the raw data show a mature diagnostics-and-life-sciences conglomerate whose organic growth has settled into low single digits and whose acquisition engine has not yet offset the lost COVID tailwind. At $194.65 the stock embeds an implied path to roughly $38–40B of revenue by the end of the decade—growth rates that would require both a sharp bioprocessing snap-back and flawless M&A integration at scale. Nothing in the last eight quarters supports that trajectory; revenue is oscillating in a $5.7–6.8B band and margins remain volatile. The 89% premium of price over the ~$105–113 DCF cluster is therefore pure story, not cash-flow support.
The strongest counter-argument is that Danaher’s installed base is genuinely sticky, gross margins hold near 59%, and FCF conversion remains excellent at roughly 145% of net income. A bull can fairly note that if GLP-1-related bioprocessing demand and cell-and-gene therapy tooling finally inflect, the operating leverage on a $24B+ revenue base could restore double-digit earnings growth and make 25–28x earnings look reasonable in hindsight. The DBS track record of margin expansion post-acquisition is real and has historically justified a conglomerate premium versus pure-play peers. Those points have merit; I simply weigh them as already fully discounted at 39x while the earnings base is still shrinking. The quality is not in dispute—the price of that quality is.
I would reverse stance only on two concrete developments: four consecutive quarters of organic revenue growth at or above 6% with operating margins expanding back through 22%, or a clear multi-year guidance raise that puts 2027–28 EPS on a path consistent with high-teens compounding. Absent that evidence, the multiple has further to compress.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Danaher is a mature, self-funding earner: FCF of $5.26B on $24.57B revenue in 2025, OCF/NI of 1.5x, accruals at -2.8% of assets, Beneish M of -2.56 and Altman Z of 4.01 all point to genuinely high-integrity earnings. Gross margin sits at a healthy 59.1% and the company is a net buyer of its own stock (diluted share CAGR -0.7%, buyback/SBC 627%, SBC only 1.2% of revenue) - per-share value is being protected, not eroded. Balance sheet carries $13.8B net debt against $4.6B cash, which is a constraint but easily serviced by consistent multi-billion FCF. The concern is trajectory, not integrity. Revenue collapsed from $31.47B (2022) to $23.88B (2024) as the COVID-era bioprocessing bulge unwound, and 2025's $24.57B is a modest 2.9% rebound. Operating margin has stepped down every year since 2022: 27.6% to 21.8% to 20.4% to 19.1%. Net income has compressed from $7.21B to $3.61B - roughly halved in three years. So the machine still works, but the profitability engine is running cooler and the multi-year trend line is down, not up. Insider tape is neutral-to-slightly-negative in tone: only routine awards, option exercises, and tax withholdings; the two open-market sells cited are small and there are zero open-market buys. Nothing alarming, but no conviction signal from management either.
Verify before trusting this (5)
- Segment-level revenue and margin detail (Biotechnology vs Life Sciences vs Diagnostics) to identify whether the OpM decline is bioprocessing-specific or broader
- Bioprocessing order book and book-to-bill trajectory to confirm whether the 2025 revenue uptick is the start of a real recovery
- Terms and maturity ladder of the debt stack given $13.8B net debt
- M&A pipeline and integration status of recent acquisitions (e.g., Abcam) and their contribution to organic vs inorganic growth
- Customer/end-market concentration in Diagnostics (Cepheid) and Biotech consumables
The three valuation lenses cluster in a tight, believable range - DCF $121.99, anchored P/E $136.25, EPV floor $71.94 - producing a composite fair value of $113.04 and a signal-adjusted $105.36. Against a $199.66 price, that is roughly 45-50% above deserved value. Even if I lean on the most generous method (anchored P/E at $136) and add a quality premium for the pristine earnings and moat, I still get a deserved price in the $140s, not $200. The EPV floor at ~$72 is telling: strip out growth optionality and current cash earnings alone do not support anywhere near today's tape.
Verify before trusting this (5)
- Bioprocessing order book and book-to-bill trend in the next print
- Diagnostics organic growth ex-China and ex-respiratory
- Segment operating margin trajectory and any guidance for margin recovery
- Capital deployment - buyback pace and any sizable M&A that would reset the model
- Whether the DCF's terminal growth and WACC assumptions are defensible given decelerating organic growth
The macro tape is mildly risk-on (VIX 15.8, S&P near highs), but with beta 0.8 and defensive-healthcare positioning, DHR barely feels the lift. The story doing the actual work here is the platform-monopoly narrative (strong intensity, moderate durability, medium cult) - it has kept the multiple stretched well above intrinsic anchors, meaning sentiment is already carrying a heavy load. That is a tailwind in place, not new fuel. Pressing the other way: the news cycle is dominated by a fresh CEO transition (Julie Sawyer Montgomery) plus a visible 'why are investors still concerned about growth?' framing, and a direct Abbott-vs-Danaher comparison in which Abbott is the one drawing the bullish analyst call. That is exactly the kind of narrative crack that de-rates platform-monopoly stories at the margin. Buybacks and an updated 2026 outlook cushion the tone but do not reset it. Net: the tape is neutral-to-slightly-positive for a low-beta defensive, the narrative is intact but under mild pressure, and analyst attention is drifting toward peers. Pressure is roughly balanced with a faint negative tilt on story momentum.
Verify before trusting this (5)
- Whether the new CEO's first public comments reinforce or dilute the DBS/M&A story
- Sell-side target revisions in the next 2-4 weeks - direction and dispersion
- Any sign of sector rotation from med-devices (ABT) back to life-sciences tools (DHR, A, TMO)
- Q3 organic growth print vs the modest guide - a miss cracks the narrative, a beat re-arms it
- VIX behavior - a move above 20 disproportionately hurts richly-priced compounders
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 6, 2026, DHR was $199.66. We expect it to be $186.50 by Feb 2027, and we consider it great value under $145.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 6, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.